Cargando…

Preferred and actual place of death in haematological malignancy

OBJECTIVES: Home is considered the preferred place of death for many, but patients with haematological malignancies (leukaemias, lymphomas and myeloma) die in hospital more often than those with other cancers and the reasons for this are not wholly understood. We examined preferred and actual place...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, D A, Wang, H I, Roman, E, Smith, A G, Patmore, R, Johnson, M J, Garry, A, Howard, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502252/
https://www.ncbi.nlm.nih.gov/pubmed/26156005
http://dx.doi.org/10.1136/bmjspcare-2014-000793
_version_ 1783248918040018944
author Howell, D A
Wang, H I
Roman, E
Smith, A G
Patmore, R
Johnson, M J
Garry, A
Howard, M
author_facet Howell, D A
Wang, H I
Roman, E
Smith, A G
Patmore, R
Johnson, M J
Garry, A
Howard, M
author_sort Howell, D A
collection PubMed
description OBJECTIVES: Home is considered the preferred place of death for many, but patients with haematological malignancies (leukaemias, lymphomas and myeloma) die in hospital more often than those with other cancers and the reasons for this are not wholly understood. We examined preferred and actual place of death among people with these diseases. METHODS: The study is embedded within an established population-based cohort of patients with haematological malignancies. All patients diagnosed at two of the largest hospitals in the study area between May 2005 and April 2008 with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma, who died before May 2010 were included. Data were obtained from medical records and routine linkage to national death records. RESULTS: 323 deceased patients were included. A total of 142 (44%) had discussed their preferred place of death; 45.8% wanted to die at home, 28.2% in hospital, 16.9% in a hospice, 5.6% in a nursing home and 3.5% were undecided; 63.4% of these died in their preferred place. Compared to patients with evidence of a discussion, those without were twice as likely to have died within a month of diagnosis (14.8% vs 29.8%). Overall, 240 patients died in hospital; those without a discussion were significantly more likely to die in hospital than those who had (p≤0.0001). Of those dying in hospital, 90% and 75.8% received haematology clinical input in the 30 and 7 days before death, respectively, and 40.8% died in haematology areas. CONCLUSIONS: Many patients discussed their preferred place of death, but a substantial proportion did not and hospital deaths were common in this latter group. There is scope to improve practice, particularly among those dying soon after diagnosis. We found evidence that some people opted to die in hospital; the extent to which this compares with other cancers is of interest.
format Online
Article
Text
id pubmed-5502252
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55022522017-07-11 Preferred and actual place of death in haematological malignancy Howell, D A Wang, H I Roman, E Smith, A G Patmore, R Johnson, M J Garry, A Howard, M BMJ Support Palliat Care Research OBJECTIVES: Home is considered the preferred place of death for many, but patients with haematological malignancies (leukaemias, lymphomas and myeloma) die in hospital more often than those with other cancers and the reasons for this are not wholly understood. We examined preferred and actual place of death among people with these diseases. METHODS: The study is embedded within an established population-based cohort of patients with haematological malignancies. All patients diagnosed at two of the largest hospitals in the study area between May 2005 and April 2008 with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma, who died before May 2010 were included. Data were obtained from medical records and routine linkage to national death records. RESULTS: 323 deceased patients were included. A total of 142 (44%) had discussed their preferred place of death; 45.8% wanted to die at home, 28.2% in hospital, 16.9% in a hospice, 5.6% in a nursing home and 3.5% were undecided; 63.4% of these died in their preferred place. Compared to patients with evidence of a discussion, those without were twice as likely to have died within a month of diagnosis (14.8% vs 29.8%). Overall, 240 patients died in hospital; those without a discussion were significantly more likely to die in hospital than those who had (p≤0.0001). Of those dying in hospital, 90% and 75.8% received haematology clinical input in the 30 and 7 days before death, respectively, and 40.8% died in haematology areas. CONCLUSIONS: Many patients discussed their preferred place of death, but a substantial proportion did not and hospital deaths were common in this latter group. There is scope to improve practice, particularly among those dying soon after diagnosis. We found evidence that some people opted to die in hospital; the extent to which this compares with other cancers is of interest. BMJ Publishing Group 2017-06 2015-07-08 /pmc/articles/PMC5502252/ /pubmed/26156005 http://dx.doi.org/10.1136/bmjspcare-2014-000793 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research
Howell, D A
Wang, H I
Roman, E
Smith, A G
Patmore, R
Johnson, M J
Garry, A
Howard, M
Preferred and actual place of death in haematological malignancy
title Preferred and actual place of death in haematological malignancy
title_full Preferred and actual place of death in haematological malignancy
title_fullStr Preferred and actual place of death in haematological malignancy
title_full_unstemmed Preferred and actual place of death in haematological malignancy
title_short Preferred and actual place of death in haematological malignancy
title_sort preferred and actual place of death in haematological malignancy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502252/
https://www.ncbi.nlm.nih.gov/pubmed/26156005
http://dx.doi.org/10.1136/bmjspcare-2014-000793
work_keys_str_mv AT howellda preferredandactualplaceofdeathinhaematologicalmalignancy
AT wanghi preferredandactualplaceofdeathinhaematologicalmalignancy
AT romane preferredandactualplaceofdeathinhaematologicalmalignancy
AT smithag preferredandactualplaceofdeathinhaematologicalmalignancy
AT patmorer preferredandactualplaceofdeathinhaematologicalmalignancy
AT johnsonmj preferredandactualplaceofdeathinhaematologicalmalignancy
AT garrya preferredandactualplaceofdeathinhaematologicalmalignancy
AT howardm preferredandactualplaceofdeathinhaematologicalmalignancy